{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgJ7fwYUKDA","lastupdate":"2023-12-06T00:00:00.000Z","update_date":"2023-12-06T00:00:00.000Z","lastModified":"Jan 27, 2025","active":1,"confidence_score":100,"confidence_score_reason":"markets","urlname":"syqe-medical","minimal_profile":null,"status":"","fullstatus":"","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$Ws03EqhM5i8jSY7f5cbfdeZw4uy5xL4j3jFDsbTOXEhN89n7uVzXwf","name":"Syqe Medical","oneliner":"Programmable Drug-delivery Inhalation Platform","registrar":"514584697","website":"https://syqe.com","careerspage":"https://syqe.com/careers","founded_month":3,"founded_year":2011,"formernames":[],"sociallinks":{"twitter":"","youtube":"https://www.youtube.com/channel/UCkBT52f5IzLc3mjWoh8RmzQ","facebook":"https://www.facebook.com/syqemedicalisrael","linkedin":"https://www.linkedin.com/company/5347518","instagram":"https://www.instagram.com/syqe.medical"},"social":["https://www.youtube.com/channel/UCkBT52f5IzLc3mjWoh8RmzQ","https://www.linkedin.com/company/5347518","https://www.instagram.com/syqe.medical","https://www.facebook.com/syqemedicalisrael"],"flattenedsociallinks":"https://www.youtube.com/channel/UCkBT52f5IzLc3mjWoh8RmzQ|https://www.linkedin.com/company/5347518|https://www.instagram.com/syqe.medical|https://www.facebook.com/syqemedicalisrael","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":null,"employees":"51-200","employees_exact":122,"patent":1,"raised":72650000,"stage":"Mature","public_stage":"Mature","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":[""],"about":"Syqe is an innovative MedTech company that developed a breakthrough technology for the administration of medical cannabis by inhalation. The SyqeAir Inhaler is a unique platform that enables physicians and patients to manage cannabis treatment safely and effectively, in compliance with the principles of the standard of care of metered dosing, lowest effective dose, and safety of use. A personalized dose for fast reduction in pain intensity and improvement in sleep quality with minimum adverse effects to establish a daily routine and improve the quality of life alongside the illness.\n\nWith each inhalation, a consistent and metered amount of THC is released from a raw medical cannabis inflorescence with a full, uniform, and consistent spectrum of the active ingredients. The cannabis is sealed in a designated cartridge, which is loaded securely into the Inhaler, ready for use. The cartridge contains 60 VaporChips (each the size of a sim card), and each VaporChip contains a uniform amount of raw cannabis inflorescence grown in compliance with GMP’s strict production requirements.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"+97235601097","country":null,"address":{"israeli":[{"id":"a62a364e-2742-42cb-acf9-0f36cbc9e7ec","city":"Tel Aviv-Yafo","type":null,"address":"HaThiya 14, Tel Aviv-Yafo, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":null},"headquarter_address":null,"district":"Center District","news":[{"id":"0aUo3fdYvmrfcz2S5AgnvK0Bsw6Z4Em3U6VKSyFj9IT2fwa1foVU0Q","date":"Jul 17, 2025","link":"https://en.globes.co.il/en/article-cannabis-inhaler-co-syqe-medical-lays-off-50-1001516332","source":"en.globes.co.il","visible":1,"analysis":{"tags":"layoffs","round":null,"company":"Syqe Medical","layoffs":50,"summary":"Syqe Medical, an Israeli cannabis inhaler company, is laying off 50 employees, which is one-third of its workforce, as part of structural adjustments mainly in the development department. The company focuses on precise and measured doses of medical cannabis through its inhaler technology. Syqe has partnerships with the Australian Department of Veterans Affairs and Israels Ministry of Defense, providing inhalers to patients with chronic pain and PTSD. The company is in the second phase of clinical trials and aims for FDA approval. Philip Morris, one of its investors, has an option to acquire Syqe based on milestones.","partners":["Australian Department of Veterans Affairs","Israels Ministry of Defense"],"customers":null,"eventType":null,"investors":["Philip Morris","Barry Shaked","Brian Cooper","OurCrowd","Shavit Capital","Martin Bauer Groups PRM"],"confidence":9,"key_topics":["cannabis","inhaler","layoffs","clinical trial","partnerships"],"date_of_event":"July 17, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":["Layoffs","Partners","Product Stage","FDA approved/pending approval"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"not mentioned","structuredIssuesShow":"#Layoffs  #Partners  #Product Stage  #FDA approved/pending approval","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"RfDkZkyLQTVtNq93NYeqKa6CG9SczQhBzBrCnbrRiFQ3eeKsXY8YoP","news_summary":"The company says it is making structural adjustments, mainly in the development department.","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"AZOtEu6UTYo0zoxO05iX33544Ny6vtCqn8zzQSqEcsLvzJwpSE0jTB","date":"Jul 16, 2025","link":"https://www.calcalistech.com/ctechnews/article/bk9fiksiel","source":"www.calcalistech.com","visible":1,"analysis":{"tags":"acquisition","round":null,"company":"Syqe Medical","layoffs":50,"summary":"Syqe Medical, an Israeli pharma-tech company, is undergoing significant changes as it awaits FDA approval for its cannabis inhaler, SyqeAir. The company has laid off 50 employees, primarily from its development department, to focus resources on securing US clearance. Syqe Medical is in the process of being acquired by Philip Morris in a deal valued at approximately $650 million, contingent on FDA approval. Philip Morris has already invested $120 million to aid in the approval process. Currently, SyqeAir is marketed only in Israel and Australia, with international expansion dependent on US regulatory success.","partners":null,"customers":null,"eventType":null,"investors":["Philip Morris","Barry Shaked","Brian Cooper","OurCrowd","Shavit Capital","PRM investment arm"],"confidence":10,"key_topics":["acquisition","FDA approval","layoffs","investment","clinical trials"],"date_of_event":"2023","product_stage":"clinical trial","investment_date":"2023","acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":120000000,"structured_issues":["Acquired-by","Layoffs","Investment","Product Stage"],"acquisition_amount":650000000,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Acquired-by  #Layoffs  #Investment  #Product Stage","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"SGYrWuSZvIF2NZUGnLr8zlglwucHyyZYsmzexn1EO1ktlOcUZI1YWN","news_summary":"The Israeli company, which in 2023 signed a deal to be acquired by Philip Morris pending FDA approval, is cutting jobs to focus resources on securing US clearance.","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"E54zshvdSUTfR6JoRQiFhfBvdIvyW3VAYUTVCZfNPcDlIKkkATSvuW","date":"Nov 1, 2023","link":"https://www.prnewswire.com/il/news-releases/syqe-medicals-revolutionary-syqeair-inhaler-obtains-artg-approval-in-australia-marking-a-historic-milestone-in-the-field-of-medicinal-cannabis-treatment-301972993.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Product Approval, Partnership","company":"Syqe Medical","layoffs":"Not mentioned","summary":"Syqe Medical, a global leader in medical inhalation technology, has received approval from the Therapeutic Goods Administration (TGA) for its SyqeAir Inhaler, marking the first and only metered-dose cannabis inhaler to obtain ARTG approval in Australia. The device is designed to administer low, metered, and consistent doses of medicinal cannabis. The cannabis inside the cartridges is cultivated under EU-GMP regulations by the Dutch company Bedrocan. Syqe has also signed a strategic agreement with the Israeli Ministry of Defense to provide its Inhaler to all its veterans suffering from chronic pain and PTSD who need medicinal cannabis treatment.","partners":"Novachem, Israeli Ministry of Defense, Bedrocan","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Product Approval","Medicinal Cannabis","Partnership","Healthcare","Innovation"],"date_of_event":"Nov. 1, 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Partners","Expand"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Partners  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"N8z1VEAJihMCt66mfMDiGjM6mVTnUUYOcIr6PNih4VQzbYEFSvwU4e","news_summary":"Syqe Medical's Revolutionary SyqeAir Inhaler Obtains ARTG Approval in Australia, Marking a Historic Milestone in the Field of Medicinal Cannabis Treatment","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"PuzCyo9Ll30160IQYvIPR1trlIWl60zQz26IKXG5zzFdIHossJ9oEp","date":"Nov 1, 2023","link":"https://nocamels.com/2023/11/australia-okays-israeli-medical-cannabis-inhaler-for-pain-relief/","source":"nocamels.com","visible":1,"analysis":{"tags":"Approval, Medical Device","company":"Syqe Medical","layoffs":"N/A","summary":"Syqe Medical, an Israeli company, has received approval from the Therapeutic Goods Administration in Australia for its SyqeAir Inhaler. The inhaler delivers precise doses of vaporized medical cannabis for pain relief. The device is the first and only metered-dose cannabis inhaler to receive such approval. The cannabis is absorbed into the patients bloodstream within minutes of inhaling a single breath, providing pain relief for several hours with minimal side effects. Each inhaler has a cartridge containing 60 single-use doses.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["Medical Cannabis","Inhaler","Australia","Approval","Pain Relief"],"date_of_event":"N/A","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":"Expand","acquisition_amount":"N/A","structuredIssuesShow":"#Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"qGHIGNW5Vltk1DDH2zVeUbAQSn8eZzOYCfOKcFIAkzdve0Rzh3BJuO","news_summary":"Australia Okays Israeli Medical Cannabis Inhaler For Pain Relief","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"H7efQfzpNsnJukVbIlim57QyHqzfvz8WUdc69R9Ab0aeMYv4z7i417","date":"Jul 18, 2023","link":"https://www.calcalistech.com/ctechnews/article/rkaylam5n","source":"www.calcalistech.com","visible":1,"analysis":{"tags":"Acquisition, Investment","company":"Syqe Medical","layoffs":"N/A","summary":"Philip Morris is acquiring Israeli company Syqe Medical in a deal that could reach $650 million. Syqes main product is a metered-dose inhaler for pain reduction treatment using medical cannabis. The deal includes an initial investment of $120 million to support the process of obtaining FDA approval for Syqes inhaler. If approval is received, Philip Morris will proceed to purchase all the shares of Syqe for $650 million. The acquisition will be conducted through Philip Morris subsidiary Vectura. Syqes inhaler is currently available in Israel and Australia.","partners":"Vectura, Ministry of Defense, Meuhedet HMO","customers":"Medical cannabis patients","investors":"Philip Morris","confidence":9,"key_topics":["Acquisition","Investment","Medical Cannabis","FDA Approval","Market Expansion"],"date_of_event":"N/A","valuation_amount":"$650 million","impact_on_company":"growth-positive","investment_amount":"$120 million","structured_issues":["Acquisition","Investment"],"acquisition_amount":"$650 million","structuredIssuesShow":"#Acquisition  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"yHsSiUMJDpfz9WZfNQQiLF2h7r2iLrVJYo20djuMvvk1Z1RUSb8Mmz","news_summary":"Philip Morris acquiring Cannabis inhaler developer Syqe Medical for up to $650 million | CTech","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"k93QLON853Mrb83TXKWA0GmJCQfwSpXhUbhRJgg5FsWaGWx27Nzxt5","date":"Jun 29, 2023","link":"https://www.jpost.com/health-and-wellness/article-748107","source":"www.jpost.com","visible":1,"analysis":{"tags":"Partnership, Healthcare","company":"Syqe","layoffs":"Not mentioned","summary":"The National Insurance Institute (NII) has entered into an exclusive agreement with Syqe, a company that develops and markets a medical cannabis inhaler. Under the agreement, NII will fully finance medical cannabis treatment for victims of hostilities, such as acts of terrorism or criminal violence. The payments will be transferred directly from the NII to Syqe. The inhaler developed by Syqe allows patients to receive a measurable and consistent dose of medical cannabis, eliminating the harms of smoking and reducing side effects.","partners":"National Insurance Institute","customers":"Victims of hostilities","investors":"National Insurance Institute","confidence":9,"key_topics":["Medical Cannabis","Inhaler","Victims of Hostilities","Healthcare","Partnership"],"date_of_event":"JUNE 29, 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Partners","Customers"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Partners  #Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"azf1zZU1HM22XukB8p4UVau9SLDXv8Of28ekzYLhTwWU2dyL5cHaaG","news_summary":"Who is entitled to funding for the new medical cannabis benefit?","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"Utbrl1kHHesfLJI2fm3IMoPl72f2eu8xhkqNvLG8ZOs3tQFPftYPx9","date":"Apr 19, 2023","link":"https://nocamels.com/2023/04/chronic-patients-hit-sweet-spot-with-cannabis-inhaler/","source":"nocamels.com","visible":1,"analysis":{"tags":"Medical Cannabis, Inhaler","company":"Syqe Medical","layoffs":"N/A","summary":"Israeli startup Syqe Medical has developed an inhaler that delivers precise doses of vaporized cannabis for pain relief. The inhaler has a cartridge containing 60 single-use doses, each dose of cannabis packed into a piece of plastic the size of a sim card. The company has conducted three clinical studies at the Rambam Hospital in northern Israel and found the therapeutic window of cannabis. The inhaler is currently used by thousands of patients in Israel and Australia, and by the end of the year, it should be rolled out to Malta and England.","partners":["Bedrocan"],"customers":["Nelly Daiboch"],"investors":"N/A","confidence":9,"key_topics":["Medical Cannabis","Pain Relief","Inhaler","Dosage Control","Expansion"],"date_of_event":"N/A","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Customers","Expand"],"acquisition_amount":"N/A","structuredIssuesShow":"#Customers  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"dZ9fUx61KFI3mFkQXbJmgqpapbHjznUbfCRGHPmz4nhMp1gKWgSu5q","news_summary":"Chronic Patients Hit 'Sweet Spot' With Cannabis Inhaler","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"19dc1f11-9f8a-497f-9234-ee99ae6e7fdd","date":"Nov 8, 2021","link":"https://www.calcalist.co.il/conferences/article/hjnmzf8dt?_atscid=7_134353_204082920_2028779_0_Txtetaxjxdshwhus8sp","source":"www.calcalist.co.il","visible":1,"analysis":{"tags":"Innovation, Cannabis","company":"Syqe Medical","layoffs":"N/A","summary":"Syqe Medicals CEO, Perry Davidson, spoke at the Cannabis Economy conference about the companys innovative approach to medical cannabis. The company has developed an inhaler that allows for consistent and measured consumption of medical cannabis. Davidson believes that innovation is the key to making medical cannabis more accessible and less stigmatized. The company has 100 patents registered on the technology and has all the regulatory approvals for Europe and Canada, and is working to obtain them in the US. The company has also conducted clinical trials and is collecting high-quality, managed data on patients.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":8,"key_topics":"Cannabis Innovation, Medical Cannabis, Regulatory Approvals, Patent Technology, Clinical Trials","date_of_event":"N/A","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":"Customers, Expand","acquisition_amount":"N/A","structuredIssuesShow":"#Customers, Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"lEZ9SmnxjO8qCjaDguAGBfwtExMCMcNyZALwWyFTsW5pmeMsDhxg8Y","news_summary":"מייסד ומנכ\"ל סאייקי מדיקל: \"המהפך יגיע כשנביא לרופאים עדויות איך טיפול בקנאביס עובד נכון\"  כלכליסט","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"cf39bb9c-76f3-42bb-8f73-4d9e9fece0bd","date":"Apr 29, 2021","link":"https://www.jpost.com/israel-news/israeli-microdosing-cannabis-inhaler-receives-approval-in-canada-europe-666690","source":"www.jpost.com","visible":1,"analysis":{"tags":"Regulatory Approval, Expansion","company":"Syqe Medical","layoffs":"NA","summary":"Israeli pharma-tech company Syqe Medical has received regulatory approval from Canadian health officials to export and sell its microdosing cannabis inhaler in Canada. The approval follows positive clinical trials at Rambam Medical Center that found microdosing cannabis can be used as an effective pain reliever while avoiding the psychoactive effects of the drug. Syqe Medical is also seeking approvals in several other European countries as well as the United States.","partners":"NA","customers":"NA","investors":"NA","confidence":9,"key_topics":["Regulatory Approval","Medical Cannabis","Microdosing","Canadian Market","Clinical Trials"],"date_of_event":"APRIL 29, 2021","valuation_amount":"NA","impact_on_company":"growth-positive","investment_amount":"NA","structured_issues":["Customers","Expand"],"acquisition_amount":"NA","structuredIssuesShow":"#Customers  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"GiBNoeHw62EaBS9z70KMVVtCsEwTrxwoNf7rqOnFPWF4L63Gpn910O","news_summary":"https://www.jpost.com/israel-news/israeli-microdosing-cannabis-inhaler-receives-approval-in-canada-europe-666690","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"d6bedaeb-8672-4d58-b884-7b17f1a95b06","date":"Jul 2, 2020","link":"https://www.israel21c.org/first-clinical-evidence-cannabis-microdoses-relieve-pain/","source":"www.israel21c.org","visible":1,"analysis":{"tags":"Medical Technology, Cannabis, Clinical Trial","company":"Syqe Medical","layoffs":"Not mentioned","summary":"Syqe Medical, an Israeli med-tech company, has conducted a clinical trial demonstrating that low and precise doses of inhaled THC, the main psychoactive component of cannabis, can effectively alleviate pain. The study, published in the European Journal of Pain, is the first scientific confirmation that microdosing works with cannabis. Patients using the Syqe Selective-Dose Inhaler, marketed in Israel by Teva, consume three to four inhalations per day, each up to 500 micrograms. Syqe believes that the study and patient use data will be an important part of its planned FDA submission in the US.","partners":"Teva","customers":"Patients","investors":"Not mentioned","confidence":9,"key_topics":"Clinical Trial, Microdosing, Pain Relief, THC, Drug Delivery Technology","date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":"Customers, Partners","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers, Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"pOczi0sE2ozDMZnSrWBMsovPdiFPr6aaYbAgXHmlqc8MKOnEebnQ2C","news_summary":"First clinical evidence: Cannabis microdoses relieve pain","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"8c7db4ce-2dbe-4226-87d4-c267c6cf85e7","date":"Jul 1, 2020","link":"https://www.ynet.co.il/articles/0,7340,L-5756215,00.html?utm_source=ynet.app.android&utm_term=5756215&utm_campaign=whatsapp&utm_medium=social","source":"www.ynet.co.il","visible":1,"analysis":{"tags":"Medical Cannabis, Microdosing","company":"Syqe Medical","layoffs":"NA","summary":"Israeli company Syqe Medical has developed a medical cannabis inhaler that allows patients to microdose their treatment. The inhaler was used in a clinical trial at Rambam Medical Center in Haifa, where researchers found that the optimal dosage for inhalation was 500 micrograms of THC. This is significantly less than the average amount consumed by patients worldwide. The inhaler allows patients to control their dosage and experience significant pain relief with minimal psychoactive side effects. The company is now working on adapting the inhaler for the administration of opioids.","partners":"Rambam Medical Center, Teva Israel","customers":"Patients at Rambam Medical Center","investors":"NA","confidence":9,"key_topics":"Medical Cannabis, Microdosing, Pain Relief, Inhaler, Clinical Research","date_of_event":"NA","valuation_amount":"NA","impact_on_company":"growth-positive","investment_amount":"NA","structured_issues":"Customers, Expand","acquisition_amount":"NA","structuredIssuesShow":"#Customers, Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Wd9dMlYMfsHkY1k9Zu1dPmFI3qFU2dGrFsl4GBlBSmf7ul24OlSCsH","news_summary":"מחקר ברמב\"ם: נמצא המינון הטיפולי המיטבי בקנאביס רפואי","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"4856118f-9bd5-4d5e-8a64-9520f1c3ab04","date":"Apr 26, 2020","link":"https://www.calcalistech.com/ctech/articles/0,7340,L-3811450,00.html","source":"www.calcalistech.com","visible":1,"analysis":{"tags":"Layoffs, Cutbacks","company":"Syqe Medical Ltd.","layoffs":"10 employees","summary":"Syqe Medical Ltd., an Israeli manufacturer of medical marijuana inhalers, is laying off 10 employees and sending another 10 on unpaid leave due to the financial impact of the Covid-19 pandemic. This represents a 10% reduction in the companys workforce. In addition, the company has implemented a company-wide pay cut for all remaining employees. Syqe, which has raised $83 million from investors including Phillip Morris, OurCrowd, Shavit Capital, and PRM, has stated that these measures are necessary to reduce personnel expenditures during the current crisis.","partners":"Not mentioned","customers":"Not mentioned","investors":["Phillip Morris","OurCrowd","Shavit Capital","PRM"],"confidence":"9","key_topics":["Covid-19 Impact","Medical Marijuana","Inhaler Manufacturer","Employee Cutbacks","Financial Crisis"],"date_of_event":"26.04.20","valuation_amount":"Not mentioned","impact_on_company":"Growth-Negative","investment_amount":"$83 million","structured_issues":["Layoffs"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Layoffs","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"Growth-Negative","analysisId":"qRfHwu0J77FOqWIhKtBJhZi2e90M1g5lXgAg9U3VzRfzTdj6hqjLlk","news_summary":"It's Not Easy Being Green: Cannabis Company Syqe to Fire 10% of Workforce","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"eda094c0-bb68-4a6a-b742-ba5339963901","date":"Mar 11, 2020","link":"https://www.prnewswire.com/news-releases/syqe-medical-named-to-fast-companys-annual-list-of-the-worlds-most-innovative-companies-for-2020-301021201.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Innovation, Biotech","company":"Syqe Medical","layoffs":"Not mentioned","summary":"Syqe Medical, an Israeli pharma-tech company, has been ranked in Fast Companys top 10 Biotech companies in the 2020 Most Innovative Companies List. The company has developed the worlds first programmable pulmonary drug delivery platform, the Syqe Inhaler, capable of administering metered doses of plants at therapeutic standards. The inhaler can deliver individually tailored daily treatment plans based on a patients clinical needs, while ensuring a consistent uniform pharmacokinetic profile. The Syqe Inhaler is used with preloaded cartridges of medical cannabis produced under pharmaceutical standards.","partners":"Teva Pharmaceuticals","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Innovation","Biotech","Medical Cannabis","Drug Delivery","Therapeutic"],"date_of_event":"March 11, 2020","valuation_amount":"Not mentioned","impact_on_company":"Growth-Positive","investment_amount":"Not mentioned","structured_issues":["Customers","Partners"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"vaXOFK3baTZbtPmDMooMubUVcp0Eme4Wu8HzpXH8QzNJDQ6DtWrBCU","news_summary":"Syqe Medical Named to Fast Company's Annual List of the World's Most Innovative Companies for 2020","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"f25a4f62-ab1c-4c8c-ae10-d9045f6368c7","date":"Sep 16, 2019","link":"https://www.prnewswire.com/news-releases/syqe-enters-into-distribution-agreement-with-terrascend-to-bring-revolutionary-medical-cannabis-treatment-to-canada-300918598.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Partnership, Medical Cannabis, Inhalation Device","company":"Syqe Medical, Ltd. and TerrAscend Corp.","layoffs":"N/A","summary":"Syqe Medical, Ltd. and TerrAscend Corp. have announced an exclusive distribution agreement to bring Syqes flagship product, the Syqe Inhaler, to the Canadian market. The Syqe Inhaler is the worlds first metered-dose medical cannabis inhaler to provide predictable, precise and consistent treatment at pharmaceutical standards. TerrAscend, through its wholly owned subsidiaries TerrAscend Canada and Solace Health Network, will lead marketing, distribution and sales efforts across Canada. The Syqe Inhaler provides an effective alternative that ensures precise dosing for cannabis delivered by inhalation, while eliminating the hazards of smoking.","partners":"TerrAscend Corp.","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["Partnership Agreement","Medical Cannabis","Inhalation Device","Canadian Market","Clinical Trials"],"date_of_event":"Sept. 16, 2019","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Partners","Expand"],"acquisition_amount":"N/A","structuredIssuesShow":"#Partners  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"15sAmhWQato9dQMMae0PBWpGuWAYk8zd090F4T4k2CrgwlzLV2YI0p","news_summary":"Syqe Enters Into Distribution Agreement With TerrAscend to Bring Revolutionary Medical Cannabis Treatment to Canada","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"9bade091-473a-4d9a-bdd3-6ad76aba9082","date":"Sep 8, 2019","link":"https://en.globes.co.il/en/article-cannabis-inhaler-co-syqe-seeks-toronto-ipo-1001299942","source":"en.globes.co.il","visible":1,"analysis":{"tags":"IPO, Investment","company":"Syqe Medical","layoffs":"N/A","summary":"Israeli company Syqe Medical is planning an IPO on the Toronto Stock Exchange. The company, which develops and markets inhalers for precise dosages of medical cannabis, has been marketed by Teva Pharmaceutical Industries since June. Syqe plans to hold its offering by the end of the year at a valuation of hundreds of millions of dollars. The company raised $50 million a year ago, the largest financing round by an Israeli cannabis company to date. The round was led by Shavit Capital, with participation from a private investor in the drug industry and the PRM Holdings fund.","partners":["Teva Pharmaceutical Industries"],"customers":"N/A","investors":["Shavit Capital","PRM Holdings fund","Ourcrowd fund","Barry Shaked","Brian Cooper","Philip Morris International"],"confidence":10,"key_topics":["IPO","Medical Cannabis","Investment","Product Development","Market Expansion"],"date_of_event":"September 8, 2019","valuation_amount":"hundreds of millions of dollars","impact_on_company":"growth-positive","investment_amount":"$50 million","structured_issues":["Public Trading","Investment"],"acquisition_amount":"N/A","structuredIssuesShow":"#Public Trading  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"oHly5d3gUO7d8r0USxivLUuGsEpGTT6avvHo9PFrhVPoYz50YG7m8D","news_summary":"Cannabis inhaler co Syqe seeks Toronto IPO","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"8b3a0d4a-f067-487f-b458-fa221185a781","date":"Jun 20, 2019","link":"https://www.calcalistech.com/ctech/articles/0,7340,L-3764680,00.html","source":"www.calcalistech.com","visible":1,"analysis":{"tags":"Product Launch, Partnership","company":"Syqe Medical Ltd.","layoffs":"Not mentioned","summary":"Tel Aviv-based cannabis company Syqe Medical Ltd. has unveiled its first cannabis inhaler after investing $83 million and eight years into its development. The company will begin distributing its product in Israel before expanding to other countries. The inhaler will be priced at approximately $545. Teva Pharmaceutical Industries Ltd. will market the companys inhalers exclusively in Israel, after signing a marketing and distribution agreement with Syqe in 2016. The company has raised a total of $83 million to date and employs a team of 100 people.","partners":"Teva Pharmaceutical Industries Ltd.","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Cannabis Inhaler","Investment","Partnership","Expansion","FDA Approval"],"date_of_event":"20.06.19","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$83 million","structured_issues":["Investment","Partners","Expand"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment  #Partners  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"NFrqk3x9CXlj8m0BF0nPfpsa7P29BGoq14Zat5EDM6fqp8CIiU43Ef","news_summary":"Eight Years and $83 Million Later, Syqe Medical Releases First Cannabis Inhaler","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"95e1bc00-81fd-4f3d-94ca-1fe4fe372b34","date":"May 7, 2019","link":"https://www.calcalistech.com/ctech/articles/0,7340,L-3761767,00.html","source":"www.calcalistech.com","visible":1,"analysis":{"tags":"Medical Cannabis, Inhaler","company":"Syqe Medical","layoffs":"Not mentioned","summary":"Syqe Medical, a Tel Aviv-based company that develops a pocket-sized metered-dose inhaler for precise delivery of cannabis molecules, has raised $80 million to date. The company plans to distribute its products in Israel via Teva Pharmaceutical Industries Ltd. The inhaler technology was developed to address the issue of dosage control in medical cannabis consumption. The companys inhalers will contain a starting dose of 250 micrograms of cannabis.","partners":"Teva Pharmaceutical Industries Ltd","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":"Medical Cannabis, Inhaler Technology, Dosage Control, Investment, Expansion","date_of_event":"07.05.19","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$80 million","structured_issues":"Investment, Expand","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment, Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"kqwYneGZ9VZrled06jlcfbEEtfW8XXRR4GLcCdHhTGSIyCJneJIv3P","news_summary":"For Medical Cannabis Users, the Biggest Problem Is a Consistent Dose, Says Syqe Medical CEO","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"10392707-1f30-4a56-895b-ec57c6cb5abc","date":"Apr 16, 2019","link":"https://www.cannabistech.com/articles/how-an-israeli-startup-solved-the-medical-cannabis-dosage-problem","source":"www.cannabistech.com","visible":1,"analysis":{"tags":"Medical Cannabis, Dosage Control","company":"Syqe Medical","layoffs":"Not mentioned","summary":"Syqe Medical, an Israeli startup, has developed a method of administering whole-plant medical cannabis that guarantees proper dosage to patients. The companys product, the Syqe Inhaler, is the worlds first pharmaceutical-grade selective-dose cannabis inhaler. The device uses thermal controllers and lung interfacing to analyze how strong or weak the user is inhaling, and can thus increase or decrease airflow according to the unique inhalation pattern of the user. The company has completed multiple successful clinical trials and is planning to conduct trials with US institutions to enter the American market.","partners":"Not mentioned","customers":"Medical Cannabis Patients","investors":"Not mentioned","confidence":9,"key_topics":"Medical Cannabis, Dosage Control, Inhaler, Clinical Trials, Expansion","date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$83 million","structured_issues":"Investment, Expand","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment, Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"u5Ag59jzyyR3v4nPxOhr4Q21YCXPKKXwvHzOTPDgaejrbg9YbvpUBK","news_summary":"How an Israeli Startup Solved the Medical Cannabis Dosage Problem","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"264dcd0d-c436-48c5-91f9-354a83aa2458","date":"Dec 31, 2018","link":"https://en.globes.co.il/en/article-cannabis-dose-inhaler-co-syqe-medical-raises-50m-1001267129","source":"en.globes.co.il","visible":1,"analysis":{"tags":"Investment, Expansion","company":"Syqe Medical","layoffs":"Not mentioned","summary":"Israeli startup Syqe Medical has raised $50 million in the largest financing round ever by an Israeli cannabis company. The company develops and markets inhalers for administering precise dosages of medical cannabis. The products are marketed in Israel by Teva Pharmaceutical Industries Ltd. The Shavit Capital fund led the round, with participation from previous investor OurCrowd, a pharma industry investor, and the PRM Holdings fund, the investment arm of therapeutic plants company Martin Bauer Group. The new financing will enable the company to develop the inhaler for other plants besides cannabis, and expand its cannabis activity from a pilot to full commercial activity in Israel and other countries.","partners":["Teva Pharmaceutical Industries Ltd.","Martin Bauer Group"],"customers":"Not mentioned","investors":["Shavit Capital fund","OurCrowd","PRM Holdings fund","Martin Bauer Group"],"confidence":9,"key_topics":["Investment","Medical Cannabis","Inhaler","Expansion","Partnerships"],"date_of_event":"December 31, 2018","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$50 million","structured_issues":["Investment","Expand"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"acYDNIi1HIdoQwEeJaAUvj8qAy1yMzwmx35zG475PZaBB1swhmOwxA","news_summary":"Cannabis smart inhaler co Syqe Medical raises $50m","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"13250967-15be-4967-a873-47b38d34a8a1","date":"Jul 29, 2018","link":"https://www.calcalistech.com/ctech/articles/0,7340,L-3743269,00.html","source":"www.calcalistech.com","visible":1,"analysis":{"tags":"Medical Cannabis, Investment, Partnership","company":"Syqe Medical","layoffs":"Not specified","summary":"Syqe Medical, a Tel Aviv-based company, has developed a pocket-sized metered-dose cannabis inhaler designed for precise delivery of natural molecules directly from plants. The company has raised $32.5 million in investment since it was founded in 2011. In 2016, Israel’s Teva Pharmaceuticals Industries Ltd. signed an agreement to distribute Syqes product in Israel. The company plans to launch the Syqe inhaler in the next few months and apply its technology to many other plants and their naturally occurring molecules.","partners":"Teva Pharmaceuticals Industries Ltd.","customers":"Not specified","investors":"Not specified","confidence":9,"key_topics":"Medical Cannabis, Investment, Inhaler, Partnership, Clinical Trials","date_of_event":"29.07.18","valuation_amount":"Not specified","impact_on_company":"growth-positive","investment_amount":"$32.5 million","structured_issues":"Investment, Partners","acquisition_amount":"Not specified","structuredIssuesShow":"#Investment, Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Q8ANrgNf3evqvkKUGVODTwACHBouXTZ0GL9x91tR8M4muGg5qhVW8Z","news_summary":"Plants Are the Future of Medicine, Says Syqe Medical Founder","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"630c3e3a-8867-4327-b32e-388f2b51fcdf","date":"Jun 5, 2018","link":"http://www.globes.co.il/en/article-syqe-medical-develops-device-for-right-cannabis-dose-1001239887","source":"www.globes.co.il","visible":1,"analysis":{"tags":"Cannabis, Medical Devices","company":"Syqe Medical","layoffs":"Not mentioned","summary":"Syqe Medical, an Israeli medical cannabis company, has received Good Manufacturing process (GMP) approval from the countrys health minister to market its cannabis in Israel. The approval covers both the device used to administer the cannabis and the plant compound itself. The company, which previously signed a marketing agreement with Teva Pharmaceutical Industries, is also planning to begin marketing its product through pharmacies. Syqe Medical was founded in 2011 to develop a measurable and repeatable method of administering medical cannabis.","partners":"Teva Pharmaceutical Industries","customers":"Not mentioned","investors":"Not mentioned","confidence":8,"key_topics":["Cannabis Marketing","Medical Devices","Partnership","Expansion","Regulation"],"date_of_event":"June 6, 2018","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Partners","Expand"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Partners  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"fG1iJhniKlIvx3Wp1BhzIhIUsW9RfjT7xzdlNF9YY5WOKbmIipKQLC","news_summary":"Syqe Medical develops device for measuring cannabis dose","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"a95c1f41-6e94-4b2e-9d82-ef1bb1e27e17","date":"Oct 18, 2017","link":"https://3dprint.com/191217/3d-printed-marijuana-inhaler/","source":"3dprint.com","visible":1,"analysis":{"tags":"Medical Marijuana, 3D Printing","company":"Syqe Medical","layoffs":"Not mentioned","summary":"Israeli drug delivery company Syqe Medical has developed a 3D printed medical marijuana inhaler. The inhaler can control the doses and dispense marijuana in a controlled treatment without any smoke or other carcinogenic materials being inhaled by the patient. Teva Pharmaceuticals will be a distributor of the device in Israel, and Syqe will seek FDA approval for the device next year. Philip Morris has invested $20 million in Syqe, accounting for two-thirds of the money invested in the startup. The inhaler reports back on when what doses have been taken, and the effects of the THC can be felt within five minutes.","partners":["Teva Pharmaceuticals","Philip Morris"],"customers":"Not mentioned","investors":["Philip Morris","Teva Pharmaceuticals"],"confidence":9,"key_topics":["3D Printing","Medical Marijuana","Inhaler","Investment","Partnership"],"date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$20 million","structured_issues":["Partners","Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"aeigxPsXdagxf2P3ME7q3LGAJWQem2qrkpg3DHvryW5nBOw0ohP0Qt","news_summary":"https://3dprint.com/191217/3d-printed-marijuana-inhaler/","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"39d7f727-258b-4ad1-bbc5-2780719e5e92","date":"Oct 15, 2017","link":"http://www.jpost.com/HEALTH-SCIENCE/3D-printed-Israeli-inhaler-transforming-how-medical-marijuana-is-prescribed-507483","source":"www.jpost.com","visible":1,"analysis":{"tags":"Medical Marijuana, Inhaler, Partnership","company":"Syqe Medical","layoffs":"Not mentioned","summary":"Syqe Medical, an Israeli medical marijuana firm, has partnered with Teva Pharmaceuticals to market and distribute a new medical marijuana inhaler. The inhaler allows doctors to prescribe the drug remotely and in controlled doses. The device is the only metered-dose cannabis and plant-material medicinal inhaler in the world. It was approved by the Health Ministry more than two years ago for use in a pilot program at Rambam Hospital in Haifa. Syqe Medical has also received a $20m investment from American tobacco giant Philip Morris. The company plans to start a trial with the US Food and Drug Administration next year.","partners":"Teva Pharmaceuticals","customers":"Patients at Rambam Hospital","investors":["Teva Pharmaceuticals","Philip Morris"],"confidence":9,"key_topics":["Medical Marijuana","Inhaler","Partnership","Investment","Expansion"],"date_of_event":"October 15, 2017","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$20m from Philip Morris","structured_issues":["Partners","Investment","Expand"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Partners  #Investment  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"oyfQuBPlbdtLB1rtDSqgx99mBPDicgyHGyr5vJ7UF12vgih27sCAfH","news_summary":"http://www.jpost.com/HEALTH-SCIENCE/3D-printed-Israeli-inhaler-transforming-how-medical-marijuana-is-prescribed-507483","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"da15bf73-9c8e-4ed2-9321-01c441a266b3","date":"Aug 20, 2017","link":"http://www.jpost.com/HEALTH-SCIENCE/Israeli-medical-cannabis-is-flying-high-502905","source":"www.jpost.com","visible":1,"analysis":{"tags":"Medical Cannabis, Health","company":"Syqe Medical","layoffs":"N/A","summary":"The 11th annual Israel Medical Conference, held in Jerusalem, dedicated half of its time to discussing the medical benefits of cannabis. The conference was attended by 1,400 people, many of whom were members of the general public. The conference discussed the potential for cannabis to be used in the treatment of a variety of diseases, including obesity, diabetes, cardiovascular disease, and cancer. The conference also discussed the potential for cannabis to be used in the treatment of pain and the side effects of chemotherapy. The conference concluded that cannabis should not be given to all patients, but should be used for specific treatments.","partners":"Teva Pharmaceutical Industries","customers":"N/A","investors":"Teva Pharmaceutical Industries","confidence":8,"key_topics":"Medical Cannabis, Health Benefits, Conference, Research, Export","date_of_event":"August 20, 2017","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":"Investment, Partners","acquisition_amount":"N/A","structuredIssuesShow":"#Investment, Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"TmCdZtLUTDJeub7j4He6wLwGibEqprfHBCgYTTfvMpJRH9gSvqSYaQ","news_summary":"http://www.jpost.com/HEALTH-SCIENCE/Israeli-medical-cannabis-is-flying-high-502905","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"9d2c11ad-e73a-468e-b023-eb08717fa5ef","date":"Jan 9, 2017","link":"https://www.timesofisrael.com/philip-morris-investment-in-syqe-was-2nd-largest-2016-cannabis-deal-report/","source":"www.timesofisrael.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"gcuKnubUZu15cEksGO05tOLedmXJBPhwpfkDsoMDmlHEreLaDrVIkj","news_summary":"Philip Morris investment in Syqe was 2nd-largest 2016 cannabis deal - report","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"ef0ef55d-06dd-4416-9fcb-c5bd6450c47a","date":"Jan 19, 2016","link":"https://www.reuters.com/article/pmi-israel/philip-morris-to-invest-20-mln-in-firm-developing-inhaler-report-idUSL8N153292","source":"www.reuters.com","visible":1,"analysis":{"tags":"Investment, Partnership","company":"Philip Morris International, Syqe Medical","layoffs":"Not mentioned","summary":"Philip Morris International is investing $20 million in Israeli start-up Syqe Medical, which has developed a metered-dose vaporiser for medical use. As part of the deal, Syqe will develop technologies for Philip Morris aimed at reducing the health risks associated with smoking. Syqe, founded in 2011, has already developed an inhaler that delivers medical cannabis in a safe and precise manner. The company plans to develop similar systems for other medicinal plants.","partners":"Syqe Medical","customers":"Not mentioned","investors":"Philip Morris International","confidence":9,"key_topics":"Investment, Medical Cannabis, Vaporiser, Health Risks, Technology Development","date_of_event":"Jan 19","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$20 million","structured_issues":"Investment, Partners","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment, Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"feWxNRD0EqvqnkuoBGEFRlT4UsQ28EyXAlzK01XxNO58CaEFAA4DP3","news_summary":"Philip Morris to invest $20 mln in firm developing inhaler -report","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"eda2aedc-22d3-44e4-831b-23ef81b7c428","date":"Sep 9, 2014","link":"http://blogs.wsj.com/middleeast/2014/09/09/cannabis-technology-venture-eyes-pain-free-future/","source":"blogs.wsj.com","visible":1,"analysis":{"tags":"Cannabis Technology","company":"Syqe Medical Ltd.","layoffs":"Not mentioned","summary":"Syqe Medical Ltd., a cannabis technology venture backed by the Israeli government, has developed a hand-held inhaler that vaporizes small doses of cannabis. This technology aims to give medical professionals more control over treatment by allowing them to administer doses as small as 1 milligram. The development of this technology could potentially make doctor-prescribed joints a thing of the past.","partners":"Not mentioned","customers":"Not mentioned","investors":"Israel government","confidence":8,"key_topics":["Cannabis Inhaler","Medical Marijuana","Technology Venture","Medical Treatment","Government Backed"],"date_of_event":"2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":"Investment","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"KnDsg3Vum0RiM6XsC2NSOFwrtDMTenedZSl9ERwMzMzsdj9TuLz4TO","news_summary":"Cannabis Technology Venture Eyes Pain Free Future","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":27,"techcommunityinvolvement":null,"mediagallery":[{"id":"55a41177-a511-4613-94dd-29b82fa59eeb","timestamp":"2017-11-23 14:20:54.000000","resources_type":1,"resources_title":"","resources_file_name":"$6d2ATEfJgIpOKpQNGOxKQRq7f49xDxNIPZhLNjGqEqCJJjd2jlTZHg","alt":"","cleanBucketUrl":"https://storage.googleapis.com/clean-finder-353810","imageurl":"https://storage.googleapis.com/clean-finder-353810/$6d2ATEfJgIpOKpQNGOxKQRq7f49xDxNIPZhLNjGqEqCJJjd2jlTZHg","url":"https://storage.googleapis.com/clean-finder-353810/$6d2ATEfJgIpOKpQNGOxKQRq7f49xDxNIPZhLNjGqEqCJJjd2jlTZHg"},{"id":"a686ea27-1fed-46e1-8bc1-5e5f7ade970f","timestamp":"2017-11-23 14:20:37.000000","resources_type":1,"resources_title":"","resources_file_name":"$6XhoIW5pDkn1V70qBw85aQXXy2wDZLh7h8WVIf3dwwDngFIUKGYEDM","alt":"","cleanBucketUrl":"https://storage.googleapis.com/clean-finder-353810","imageurl":"https://storage.googleapis.com/clean-finder-353810/$6XhoIW5pDkn1V70qBw85aQXXy2wDZLh7h8WVIf3dwwDngFIUKGYEDM","url":"https://storage.googleapis.com/clean-finder-353810/$6XhoIW5pDkn1V70qBw85aQXXy2wDZLh7h8WVIf3dwwDngFIUKGYEDM"},{"id":"922dc89c-8233-45a5-9475-9d5f184ac07e","timestamp":"2014-12-10 08:44:41.000000","resources_type":2,"resources_title":"","resources_file_name":"miUYb_V2GMU","alt":"","imageurl":"https://img.youtube.com/vi/miUYb_V2GMU/0.jpg","url":"http://youtu.be/miUYb_V2GMU"}],"tags":["cannabis","pharmaceuticals","drug-delivery","medical-devices","inhalation","patients","medical-technologies","chronic-pain","chronic-patients","medical-cannabis","data-analytics","pain-relief","sleep-disorders","cns-disorders","therapeutics"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuMqZMJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7rMLDA"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2B","B2C"],"productstage":"Released","products":["SyqeAir Inhaler"],"geomarkets":["Australia","United Kingdom","Canada","Germany","United States","Israel"],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":7,"lastfunding":"$50M","totalrounds":3,"fundingstage":"Mature","totalfunding":"$72.65M","publicinvestors":7,"lastpublicfunding":50000000,"totalpublicrounds":3,"totalpublicfunding":72650000},"team":[{"name":"Perry Davidson","email":"perry@syqemed.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgJ6-msIIDA","bounced":false,"claimed":0,"founder":1,"urlname":"perry-davidson","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICA3o7WiAkM","position":"Founder & CEO","last_name":"Davidson","claimtoken":"ZVBqIDkJIgKQx3K7ULhH8kTeApqoUW1VBR8iqRMhXPPMLe2PRIWo0q","first_name":"Perry","picturekey":null,"claimeddate":null,"linkedinurl":null,"unsubscribed":false,"is_activeuser":0,"additionalemail":"perry.davidson@syqemed.com","claimedemaildate":"2022-09-28 18:09:50.000000","initials":"PD","pictureurl":"/assets/empty-state.svg","linkedin-display":"none","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Benny Shwartz","email":"benny@syqemedical.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoNLpq6MKDA","bounced":false,"claimed":0,"founder":0,"urlname":"benny-shwartz","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICg0p2j3QgM","position":"COO","last_name":"Shwartz","claimtoken":"aK1P0Y5wVCew1omh8OmpgCr5OPXoKYEX0aB64qkBwCYOQeZe3L8RfZ","first_name":"Benny","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/benny-shwartz-1b9a8540/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2023-12-05 13:49:16.000000","initials":"BS","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Lior Levin","email":"lior@syqemedical.com","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoNmykd0LDA","bounced":false,"claimed":0,"founder":0,"urlname":"lior-levin-4","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICg2YO1hAgM","position":"HR Manager","last_name":"Levin","claimtoken":"MY8gI7Pyo60ekTvYDqdboxKGyGlCdEh1kmOtM56cbHEdGHcYSh21Ex","first_name":"Lior","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/liorlevin1/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2023-12-05 13:49:20.000000","initials":"LL","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Digital Health and Medical Technologies","sectorverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgN7UwIEIDA","fullname":"Aviv Alper"},"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgMGgoMMJDA","fullname":"Yanina Wainscheinker"},"biverifydate":"2020-05-14T00:00:00.000Z","crunchbaseid":"syqe-medical","lastupdator":"Yanina Wainscheinker","lastupdator_email":"yanina.wainscheinker@sncentral.org","creator":null,"creator_email":null,"createdate":"2014-11-16T00:00:00.000Z","biverification":"Yanina Wainscheinker","sectorverification":"Aviv Alper","affiliatedOrganizations":null,"timeline":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCk2pqwCww","date":"Dec 2018","amount":"$50M","source":"Migrated , https://docs.google.com/spreadsheets/d/1E3q3rI50x7dJusZbCTI9bYD7tM6EaSa6Fv5WCYk5F0A/edit#gid2031243637","eventtype":"FundingRoundEvent","investment":[{"name":"PRM Holdings Fund","type":"Investor","amount":0,"hidden":false,"country":"Germany","fullurl":"/investor_page/prm-holdings-fund","logokey":null,"tagline":"","urlname":"/investor_page/prm-holdings-fund","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCkmqnaCgw","fundingtype":"Corporate VC","leadpartner":null,"investmentid":"JoNActhe5pOCgHW4qs5TjayDJ4t8Ka3byMMy95WAHnfZdQeLyn5ljJ","fundingsubtype":"Corporate VC","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"Shavit Capital Fund","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/shavit-capital-fund","logokey":"$vA62KRr8oAhlRh6QpynFhpg7usvk9m5bS7RnGX6t7fqsS2w1MGMsD9","tagline":null,"urlname":"/investor_page/shavit-capital-fund","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgNG_lJEKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"LJ5i4xyvN89QSbdOCeElE0VoOI4mRM5cBHcpfI9N1m9Jqh9SqMqWgv","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$vA62KRr8oAhlRh6QpynFhpg7usvk9m5bS7RnGX6t7fqsS2w1MGMsD9","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"OurCrowd","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/ourcrowd","logokey":"$7IbHrXXd8dSbWrifZtvAYNCvwQvEjxCgGJeOg7DXKENs3TbpV3W9g1","tagline":null,"urlname":"/investor_page/ourcrowd","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgP7H-oQKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"Ucxs4VTrErrs2KJScuaj89bp8O3gR9AdbKPDHsfBSgpZyYsqhPX9n4","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$7IbHrXXd8dSbWrifZtvAYNCvwQvEjxCgGJeOg7DXKENs3TbpV3W9g1","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"B Round","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":50000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCE7ur2CAw","date":"Dec 2015","amount":"$20M","source":"https://www.reuters.com/article/pmi-israel-idUSL8N153292/","eventtype":"FundingRoundEvent","investment":[{"name":"Brian Cooper","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/brian-cooper","logokey":null,"tagline":"","urlname":"/investor_page/brian-cooper","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCk8afKCAw","fundingtype":"Angel","leadpartner":null,"investmentid":"18372a87-fe20-42b8-970b-938cc78949a8","fundingsubtype":"Angel","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":"Follow on "},{"name":"OurCrowd","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/ourcrowd","logokey":"$7IbHrXXd8dSbWrifZtvAYNCvwQvEjxCgGJeOg7DXKENs3TbpV3W9g1","tagline":null,"urlname":"/investor_page/ourcrowd","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgP7H-oQKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"2b74ea76-9206-44bf-9aeb-a6f40b3df437","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$7IbHrXXd8dSbWrifZtvAYNCvwQvEjxCgGJeOg7DXKENs3TbpV3W9g1","leadcaption":"","followupcaption":""},{"name":"Barry Shaked","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/barry-shaked","logokey":null,"tagline":"","urlname":"/investor_page/barry-shaked","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCk2q_ACgw","fundingtype":"Angel","leadpartner":null,"investmentid":"9eccfa0d-1a9e-4d1b-994f-900ed8539bdf","fundingsubtype":"Angel","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":"Follow on "},{"name":"Philip Morris","type":"Company","amount":0,"hidden":true,"country":"United States","fullurl":"/company_page/philip-morris","logokey":"$VbkzxoLUftT8nXwX461Rbu1C6UiUxeRU4MwdiveEAwT1ALRre44YoO","tagline":"Cigarette & Tobacco Manufacturing Company","urlname":"/company_page/philip-morris","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE3L3GCgw","fundingtype":"Company","leadpartner":null,"investmentid":"a58c5738-d96b-4b05-9a02-07c7cbea85e4","fundingsubtype":"","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$VbkzxoLUftT8nXwX461Rbu1C6UiUxeRU4MwdiveEAwT1ALRre44YoO","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":20000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODkntTCCww","date":"Dec 2014","amount":"$2.65M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Brian Cooper","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/brian-cooper","logokey":null,"tagline":"","urlname":"/investor_page/brian-cooper","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCk8afKCAw","fundingtype":"Angel","leadpartner":null,"investmentid":"64cc31c6-e55e-4441-99a5-25b67d224dbe","fundingsubtype":"Angel","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""},{"name":"Barry Shaked","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/barry-shaked","logokey":null,"tagline":"","urlname":"/investor_page/barry-shaked","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCk2q_ACgw","fundingtype":"Angel","leadpartner":null,"investmentid":"b2e2b0f0-f097-4705-8939-89165429ad12","fundingsubtype":"Angel","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""},{"name":"Angel Investor - Eitan Shapiro","type":"Investor","amount":0,"hidden":false,"country":"US","fullurl":"/investor_page/angel-investor-eitan-shapiro","logokey":null,"tagline":"","urlname":"/investor_page/angel-investor-eitan-shapiro","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODEtcuTCAw","fundingtype":"Angel","leadpartner":null,"investmentid":"b3450718-9af0-4153-9514-8f507ba30779","fundingsubtype":"Angel","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":2650000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"3/2011","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"Syqe Medical","logourl":"https://storage.googleapis.com/clean-finder-353810/$Ws03EqhM5i8jSY7f5cbfdeZw4uy5xL4j3jFDsbTOXEhN89n7uVzXwf","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$Ws03EqhM5i8jSY7f5cbfdeZw4uy5xL4j3jFDsbTOXEhN89n7uVzXwf","seoabout":"Syqe is an innovative MedTech company that developed a breakthrough technology for the administration of medical cannabis by inhalation. The SyqeAir Inhale...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":3,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Medical Cannabis","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gJDA","classificationName":"sectorclassification"},{"depth":2,"name":"Medical Devices","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA","classificationName":"sectorclassification"},{"depth":3,"name":"Medical Treatment & Therapeutics","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Materials & Substances","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA","classificationName":"coretechnology"},{"depth":2,"name":"Raw Materials","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuMqZMJDA","classificationName":"coretechnology"},{"depth":1,"name":"Semiconductors & Electronics","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7rMLDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Patients","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","TechnologyClassificationModel>Materials & Substances#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA>Medical Treatment & Therapeutics#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA>Patients#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Medical Cannabis#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gJDA","TechnologyClassificationModel>Materials & Substances#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA>Raw Materials#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuMqZMJDA","TechnologyClassificationModel>Semiconductors & Electronics#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7rMLDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Medical Cannabis#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gJDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA/Medical Treatment & Therapeutics#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Materials & Substances#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA|2:>TechnologyClassificationModel>Materials & Substances#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA/Raw Materials#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuMqZMJDA|1:>TechnologyClassificationModel/Semiconductors & Electronics#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7rMLDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA/Patients#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Medical Cannabis","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Medical Cannabis"}]},{"title":"Medical Devices","key":"0-0-1","path":"SectorClassificationModel>Health Tech & Life Sciences>Medical Devices","children":[{"title":"Medical Treatment & Therapeutics","key":"0-0-1-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Medical Devices>Medical Treatment & Therapeutics"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Healthcare","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare","children":[{"title":"Patients","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare>Patients"}]}]}],"coreTechnology":[{"title":"Materials & Substances","key":"0-0","path":"TechnologyClassificationModel>Materials & Substances","children":[{"title":"Raw Materials","key":"0-0-0","path":"TechnologyClassificationModel>Materials & Substances>Raw Materials"}]},{"title":"Semiconductors & Electronics","key":"0-1","path":"TechnologyClassificationModel>Semiconductors & Electronics"}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Medical Cannabis","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gJDA","classificationName":"sectorclassification"},{"depth":2,"name":"Medical Devices","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA","classificationName":"sectorclassification"},{"depth":3,"name":"Medical Treatment & Therapeutics","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Materials & Substances","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA","classificationName":"coretechnology"},{"depth":2,"name":"Raw Materials","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuMqZMJDA","classificationName":"coretechnology"},{"depth":1,"name":"Semiconductors & Electronics","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7rMLDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Patients","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Medical Cannabis","Medical Devices","Medical Treatment & Therapeutics"],"coreTechnology":["Materials & Substances","Raw Materials","Semiconductors & Electronics"],"targetCustomer":["Healthcare & Life Sciences","Healthcare","Patients"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"none","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCk2pqwCww","date":"Dec 2018","amount":"$50M","source":"Migrated , https://docs.google.com/spreadsheets/d/1E3q3rI50x7dJusZbCTI9bYD7tM6EaSa6Fv5WCYk5F0A/edit#gid2031243637","eventtype":"FundingRoundEvent","investment":[{"name":"PRM Holdings Fund","type":"Investor","amount":0,"hidden":false,"country":"Germany","fullurl":"/investor_page/prm-holdings-fund","logokey":null,"tagline":"","urlname":"/investor_page/prm-holdings-fund","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCkmqnaCgw","fundingtype":"Corporate VC","leadpartner":null,"investmentid":"JoNActhe5pOCgHW4qs5TjayDJ4t8Ka3byMMy95WAHnfZdQeLyn5ljJ","fundingsubtype":"Corporate VC","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"Shavit Capital Fund","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/shavit-capital-fund","logokey":"$vA62KRr8oAhlRh6QpynFhpg7usvk9m5bS7RnGX6t7fqsS2w1MGMsD9","tagline":null,"urlname":"/investor_page/shavit-capital-fund","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgNG_lJEKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"LJ5i4xyvN89QSbdOCeElE0VoOI4mRM5cBHcpfI9N1m9Jqh9SqMqWgv","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$vA62KRr8oAhlRh6QpynFhpg7usvk9m5bS7RnGX6t7fqsS2w1MGMsD9","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"OurCrowd","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/ourcrowd","logokey":"$7IbHrXXd8dSbWrifZtvAYNCvwQvEjxCgGJeOg7DXKENs3TbpV3W9g1","tagline":null,"urlname":"/investor_page/ourcrowd","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgP7H-oQKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"Ucxs4VTrErrs2KJScuaj89bp8O3gR9AdbKPDHsfBSgpZyYsqhPX9n4","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$7IbHrXXd8dSbWrifZtvAYNCvwQvEjxCgGJeOg7DXKENs3TbpV3W9g1","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"B Round","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":50000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCE7ur2CAw","date":"Dec 2015","amount":"$20M","source":"https://www.reuters.com/article/pmi-israel-idUSL8N153292/","eventtype":"FundingRoundEvent","investment":[{"name":"Brian Cooper","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/brian-cooper","logokey":null,"tagline":"","urlname":"/investor_page/brian-cooper","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCk8afKCAw","fundingtype":"Angel","leadpartner":null,"investmentid":"18372a87-fe20-42b8-970b-938cc78949a8","fundingsubtype":"Angel","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":"Follow on "},{"name":"OurCrowd","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/ourcrowd","logokey":"$7IbHrXXd8dSbWrifZtvAYNCvwQvEjxCgGJeOg7DXKENs3TbpV3W9g1","tagline":null,"urlname":"/investor_page/ourcrowd","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgP7H-oQKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"2b74ea76-9206-44bf-9aeb-a6f40b3df437","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$7IbHrXXd8dSbWrifZtvAYNCvwQvEjxCgGJeOg7DXKENs3TbpV3W9g1","leadcaption":"","followupcaption":""},{"name":"Barry Shaked","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/barry-shaked","logokey":null,"tagline":"","urlname":"/investor_page/barry-shaked","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCk2q_ACgw","fundingtype":"Angel","leadpartner":null,"investmentid":"9eccfa0d-1a9e-4d1b-994f-900ed8539bdf","fundingsubtype":"Angel","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":"Follow on "},{"name":"Philip Morris","type":"Company","amount":0,"hidden":true,"country":"United States","fullurl":"/company_page/philip-morris","logokey":"$VbkzxoLUftT8nXwX461Rbu1C6UiUxeRU4MwdiveEAwT1ALRre44YoO","tagline":"Cigarette & Tobacco Manufacturing Company","urlname":"/company_page/philip-morris","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE3L3GCgw","fundingtype":"Company","leadpartner":null,"investmentid":"a58c5738-d96b-4b05-9a02-07c7cbea85e4","fundingsubtype":"","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$VbkzxoLUftT8nXwX461Rbu1C6UiUxeRU4MwdiveEAwT1ALRre44YoO","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":20000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODkntTCCww","date":"Dec 2014","amount":"$2.65M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Brian Cooper","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/brian-cooper","logokey":null,"tagline":"","urlname":"/investor_page/brian-cooper","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCk8afKCAw","fundingtype":"Angel","leadpartner":null,"investmentid":"64cc31c6-e55e-4441-99a5-25b67d224dbe","fundingsubtype":"Angel","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""},{"name":"Barry Shaked","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/barry-shaked","logokey":null,"tagline":"","urlname":"/investor_page/barry-shaked","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCk2q_ACgw","fundingtype":"Angel","leadpartner":null,"investmentid":"b2e2b0f0-f097-4705-8939-89165429ad12","fundingsubtype":"Angel","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""},{"name":"Angel Investor - Eitan Shapiro","type":"Investor","amount":0,"hidden":false,"country":"US","fullurl":"/investor_page/angel-investor-eitan-shapiro","logokey":null,"tagline":"","urlname":"/investor_page/angel-investor-eitan-shapiro","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODEtcuTCAw","fundingtype":"Angel","leadpartner":null,"investmentid":"b3450718-9af0-4153-9514-8f507ba30779","fundingsubtype":"Angel","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":2650000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[],"merger_acquisitions":[],"others":[]}}